PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Circ Res. Author manuscript; available in PMC 2017 April 1.
Published in final edited form as:
PMCID: PMC4819164
NIHMSID: NIHMS765962

Duchenne muscular dystrophy mice and men: Can understanding a genetic cardiomyopathy inform treatment of other myocardial diseases?

Summary

Duchenne muscular dystrophy (DMD) mouse models have a predictable and reproducible time-course of cardiomyopathy progression with discrete pathogenic steps, which closely parallel what we know occurs in the cardiomyopathy of patients with DMD. The slow progression of early pathogenic steps common to many cardiomyopathies may make DMD models useful for identifying novel treatment targets and testing the therapeutic value of new treatment paradigms for an at-risk patient population far beyond those with muscular dystrophies.

Keywords: dystrophin, cardiomyopathy, heart, mineralocorticoid receptor, claudin-5

Dilated cardiomyopathy (DCM) is a leading cause of death in individuals affected by Duchenne muscular dystrophy (DMD), and nearly all DMD patients develop DCM by age 18. DMD and the milder Becker muscular dystrophy result from mutations in the X-linked gene encoding dystrophin, a membrane-associated protein that helps protect striated muscle cell membranes from damage. Clinical signs resulting from lower limb muscle weakness lead to DMD diagnosis typically by 5 years-of-age and loss of ambulation by 12 years-of-age. Skeletal myopathy in Becker muscular dystrophy has a later age of onset and slower progression than DMD and DCM is the primary cause of mortality. Earlier ventilatory support for affected respiratory muscles and timely management of pulmonary infections have led to increased survival for DMD patients into their mid twenties. These advances have made increasingly evident the underlying cardiomyopathy that presents as heart failure and often fatal arrhythmias in the later decades of life.

Despite the devastating consequences of DMD cardiomyopathy, its unique features may provide new insights into myocardial disease. First, the consistent lag between evident skeletal myopathy and cardiomyopathy affords early detection and possible treatment of a patient population that is genetically programmed to develop cardiac dysfunction. Second, the myocardial disease exhibits a relatively slow progression, providing the ability to understand each step involved. Third, there are isogenic mouse models of DMD, additional mouse models that have been created to represent a spectrum of dystrophic myocardial disease, and large animal models. Over the past 15 years, these three features have allowed the progression of the DMD cardiomyopathy to be functionally dissected in parallel human and mouse studies.

Steps in dystrophic cardiomyopathy

There are three dystrophic mouse models with different severities of myocardial weakness and damage that have been used to dissect out the steps of dystrophic cardiomyopathy. Dystrophin-deficient mdx mice are the isogenic model for DMD, but have a late onset cardiac phenotype that makes studying the pathogenesis and testing treatments a lengthy and expensive process1. Mdx mice also deficient for the dystrophin paralog, utrophin, have the most severe cardiac pathology with reduced myocardial force, and extensive cardiomyocyte damage and fibrosis by 10 weeks-of-age. Working with this model is complicated by their death typically between 10 and 20 week-of-age resulting from their skeletal muscle pathology2. Mdx mice lacking one copy of a functional utrophin gene develop quantitatively more fibrosis in skeletal muscles over time than mdx mice and exhibit a faster progression of myocardial weakness and cardiomyocyte damage3.

Using these three strains, many studies by our team and others have shown that there are discrete pathogenic characteristics that occur in these models, where initiation of each step reproducibly precedes the initiation of the following step. The first step in the dystrophic cardiomyopathy is myocardial muscle weakness and a blunted β-adrenergic response4. The next detectable step is cardiomyocyte damage that can be easily observed by the uptake of a vital dye such as Evan's Blue, or can be quantified in histological sections by accumulation of serum proteins within cardiomyocytes5. Cardiomyocyte damage is ongoing with a relatively small percentage of dying cells at any one time-point. As this damage progresses, areas of myocyte damage become invaded by fibroblasts producing matrix metalloproteinases (MMPs) and there is a concomitant reduction in tissue inhibitors of metalloproteinases (TIMPs)3, 6. This process results in replacement of dead cardiomyocytes with fibrotic scars. A remarkable amount of fibrosis accumulates prior to any reduction in ejection fraction3, 6.

A decade of bench-to-bedside-and-back collaboration studying DMD mouse models and patients along with improved imaging techniques have led to substantial advances in understanding DMD cardiomyopathy. Abnormal myocardial strain by cardiac magnetic resonance (CMR) is the first detectable sign of cardiac dysfunction in DMD patients7, 8. Measuring myocardial strain in dystrophic mice demonstrates a close correlation between in vivo abnormalities in strain and in vitro reductions in myocardial muscle force3, 4. In a study of 1768 asymptomatic individuals age 55–75 years who underwent CMR with tagged cine imaging affording strain computation, myocardial circumferential strain (Ecc) was independently and incrementally predictive of symptomatic heart failure over 5 years follow-up in a multiethnic population9. Circumferential strain measured by speckle tracking echocardiography in a large cohort of Framingham Offspring Study participants was also found to be predictive of heart failure10. Thus, considerable data has accrued supporting myocardial strain abnormalities as an early indicator of developing cardiac dysfunction across a broad range of individuals at risk of cardiomyopathy and heart failure.

The histological damage that is observed as the second step in all dystrophic mouse models, is ongoing and appears to involve a relatively slow rate of cardiomyocyte death, compared with the massive coordinated cell death present after an ischemic event, for instance. This observation of ongoing damage is supported in DMD patients through episodic detection of elevated troponin-I levels and accrual of myocardial injury by serial late gadolinium enhancement imaging7, 11. The increases in MMP-2 and MMP-9 and reductions of TIMPs that occur in dystrophic hearts are also conserved across most human heart failure populations and therefore have been a target for therapeutic development.

The accumulation of myocardial damage is inevitably replaced by fibrotic scarring. The fibrotic accumulation in the most rapidly progressing DMD mouse model is often in a crescent pattern in the epicardial layer of the left ventricle6. However, diffuse fibrosis is typically also present throughout both the left and right ventricles in the mouse models and continues to accumulate throughout both ventricles over the lifespan of the mice. Again, relatively recent advancements in imaging capabilities have led to the ability to detect myocardial damage using CMR with late gadolinium enhancement imaging (LGE). Notably, all DMD patients show a consistent initial pattern of enhancement in a crescent in the epicardium of the left ventricular free wall6, 12. LGE is also predictive of adverse outcomes in other cardiomyopathy patient populations, including patients with nonischemic cardiomyopathy13. Importantly, and in parallel with DMD mouse models, this damage in DMD patients is detectable by LGE many years before reduced ejection fraction can be detected by echocardiography. These observations identify a large window for therapeutic interventions for DMD patients and have altered clinical practice in screening for cardiomyopathy and initiating standard-of-care cardioprotective medications, while fueling investigation of therapies that may be beneficial at earlier stages of myocardial disease.

Bench-to-Bedside directed improvements in patient care and therapeutic testing

Advances in parallel preclinical and human studies are being incorporated into updated recommendations for monitoring and treatment for DMD patients as well as testing potential therapeutics at earlier stages of disease. A Working Group meeting, sponsored by NHLBI and Parent Project Muscular Dystrophy, was held in summer 2014 to address Contemporary Issues in DMD Cardiomyopathy14. This meeting led to updating the DMD Care Considerations to include earlier surveillance employing use of CMR to improve the diagnosis and management of DMD cardiomyopathy and for use in monitoring clinical trials in this population. The group also recommended use of angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) by the age of 10 or earlier.

Using a bench-to-beside approach, our team tested early addition of a mineralocorticoid receptor antagonist (MRA), typically used in advanced heart failure, as an anti-fibrotic drug in a DMD mouse model3. This study showed that the earliest use of an MRA added to standard-of-care ACEi resulted in a dramatic reduction in cardiac damage and a dramatic improvement in cardiac strain measurements. We then executed a placebo-controlled double-blind clinical trial, translating this approach to DMD patients with evident myocardial damage by LGE but preserved ejection fraction by cine CMR; this approach attenuated decline of LV circumferential strain in patients with DMD15. In addition, there was less reduction in ejection fraction over the course of the study. These data further support the benefit of earlier therapeutic intervention in DMD cardiomyopathy rather than waiting to start treatment after the ejection fraction falls.

Translation between DMD mouse models and other cardiomyopathies

DMD mouse models have a predictable and reproducible time-course and relatively slow cardiomyopathy progression that can be separated into discrete steps, which closely parallel data from DMD patients. These characteristics that include reduced myocardial strain, depressed β-adrenergic response, increased MMP activity, and accumulation of fibrosis, are all conserved across a wide variety of cardiomyopathies. Therefore, information about the pathogenesis and treatment in DMD models and patients may be applicable in identifying novel treatment targets and approaches for the broader population of patients with DCM.

As an example, we identified a reduction in transcript and resulting protein levels of the claudin-5 gene in the most severe DMD model. This reduction occurs over a 2-week period coincident with the initial onset of cardiomyocyte damage, long before reduced ejection fraction16. Exogenous expression of claudin-5 in heart is able to prevent the initial reductions in myocardial force and myocardial damage in this DMD model16. We then identified dramatically reduced claudin-5 protein levels in the vast majority of cardiac explant samples from over 75 heart failure patients in comparison with non-failing human donors17, 18. Therefore, molecular events occurring early in the progression of dystrophic cardiomyopathy may represent novel treatment targets applicable for a patient population far beyond DMD. Conversely, therapeutics used for other forms of cardiomyopathy or heart failure may be able to target the steps common with DMD cardiomyopathy and improve morbidity. Rapid progression in other mouse models, such as induced pressure-overload and coronary artery ligation models, have essential roles for understanding particular disease initiators and may be helpful in understanding symptomatic heart failure, but are less informative when testing therapeutic strategies targeting early pathogenic steps that evolve over years in patients. The reproducibility and slow progression of early pathogenic steps common to many cardiomyopathies support the potential utility of DMD models for identifying novel treatment targets and testing the therapeutic value of new treatment paradigms for a wider patient population.

Acknowledgments

Sources of Funding: The authors are supported in part by the National Institutes of Health R01 HL116533 (JRF and SVR) and R01 NS082868 (JRF and JAC), Department of Defense MD120063 (JRF), and the National Center for Advancing Translational Sciences UL1TR000090,UL1TR000124 (SVR).

Footnotes

Disclosures: None of the authors have any relevant conflicts to report.

References

1. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord. 2004;14:491–496. [PubMed]
2. Rafael JA, Tinsley JM, Potter AC, Deconinck AE, Davies KE. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet. 1998;19:79–82. [PubMed]
3. Rafael-Fortney JA, Chimanji NS, Schill KE, Martin CD, Murray JD, Ganguly R, Stangland JE, Tran T, Xu Y, Canan BD, Mays TA, Delfin DA, Janssen PM, Raman SV. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in duchenne muscular dystrophy mice. Circulation. 2011;124:582–588. [PMC free article] [PubMed]
4. Janssen PM, Hiranandani N, Mays TA, Rafael-Fortney JA. Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol. 2005;289:H2373–H2378. [PubMed]
5. Hainsey TA, Senapati S, Kuhn DE, Rafael JA. Cardiomyopathic features associated with muscular dystrophy are independent of dystrophin absence in cardiovasculature. Neuromuscul Disord. 2003;13:294–302. [PubMed]
6. Delfin DA, Zang KE, Schill KE, Patel NT, Janssen PM, Raman SV, Rafael-Fortney JA. Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases. Neuromuscul Disord. 2012;22:1006–1014. [PMC free article] [PubMed]
7. Hor KN, Wansapura J, Markham LW, Mazur W, Cripe LH, Fleck R, Benson DW, Gottliebson WM. Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study. J Am Coll Cardiol. 2009;53:1204–1210. [PMC free article] [PubMed]
8. Hor KN, Kissoon N, Mazur W, Gupta R, Ittenbach RF, Al-Khalidi HR, Cripe LH, Raman SV, Puchalski MD, Gottliebson WM, Benson DW. Regional circumferential strain is a biomarker for disease severity in duchenne muscular dystrophy heart disease: a cross-sectional study. Pediatric cardiology. 2015;36:111–119. [PubMed]
9. Choi EY, Rosen BD, Fernandes VR, Yan RT, Yoneyama K, Donekal S, Opdahl A, Almeida AL, Wu CO, Gomes AS, Bluemke DA, Lima JA. Prognostic value of myocardial circumferential strain for incident heart failure and cardiovascular events in asymptomatic individuals: the Multi-Ethnic Study of Atherosclerosis. Eur Heart J. 2013;34:2354–2361. [PMC free article] [PubMed]
10. Cheng S, McCabe EL, Larson MG, Merz AA, Osypiuk E, Lehman BT, Stantchev P, Aragam J, Solomon SD, Benjamin EJ, Vasan RS. Distinct Aspects of Left Ventricular Mechanical Function Are Differentially Associated With Cardiovascular Outcomes and All-Cause Mortality in the Community. Journal of the American Heart Association. 2015;4 [PMC free article] [PubMed]
11. Matsumura T, Saito T, Fujimura H, Shinno S. Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients. Brain & development. 2007;29:496–501. [PubMed]
12. Hor KN, Taylor MD, Al-Khalidi HR, Cripe LH, Raman SV, Jefferies JL, O'Donnell R, Benson DW, Mazur W. Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function. J Cardiovasc Magn Reson. 2013;15:107. [PMC free article] [PubMed]
13. Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014;7:250–258. [PMC free article] [PubMed]
14. McNally EM, Kaltman JR, Benson DW, et al. Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation. 2015;131:1590–1598. [PMC free article] [PubMed]
15. Raman SV, Hor KN, Mazur W, et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14:153–161. [PMC free article] [PubMed]
16. Delfin DA, Xu Y, Schill KE, Mays TA, Canan BD, Zang KE, Barnum JA, Janssen PM, Rafael-Fortney JA. Sustaining cardiac claudin-5 levels prevents functional hallmarks of cardiomyopathy in a muscular dystrophy mouse model. Mol Ther. 2012;20:1378–1383. [PubMed]
17. Mays TA, Binkley PF, Lesinski A, Doshi AA, Quaile MP, Margulies KB, Janssen PM, Rafael-Fortney JA. Claudin-5 levels are reduced in human end-stage cardiomyopathy. J Mol Cell Cardiol. 2008;45:81–87. [PubMed]
18. Swager SA, Delfin DA, Rastogi N, Wang H, Canan BD, Fedorov VV, Mohler PJ, Kilic A, Higgins RS, Ziolo MT, Janssen PM, Rafael-Fortney JA. Claudin-5 levels are reduced from multiple cell types in human failing hearts and are associated with mislocalization of ephrin-B1. Cardiovasc Pathol. 2015;24:160–167. [PMC free article] [PubMed]